SoluBest and Dr. Reddy´s Sign Drug Delivery Collaboration to Develop New, Proprietary Formulations
SoluBest has closed a collaboration agreement with Dr. Reddy's Laboratories Ltd. to develop a new, proprietary formulation of one of SoluBest’s pipeline compound.. In return, SoluBest is eligible to upfront, research and milestone and significant royalty payments. Further financial details have not been disclosed.
SoluBest has developed its Solumer™ technology platform to address solubility issues, one of the most pressing problems in drug development and drug delivery: About 40% of marketed drugs are thought to be poorly water soluble, and it is estimated that up to 70% of new chemical entities (NCEs) entering drug development programs possess insufficient aqueous solubility to allow adequate and consistent gastrointestinal absorption to ensure efficacy.
The Solumer™ platform is based on the self-assembly of selected FDA-approved polymer compounds, creating highly stable particles in which API molecules are interwoven into the polymer matrix. Once formulations come in contact with aqueous media, they spontaneously form colloidal dispersions, resulting in increased bioavailability of the active pharmaceutical ingredient. The process is easily adaptable to a wide range of molecules, requiring limited customization for each, and involves a simple 2 step procedure—the preparation of a liquid feed followed by its spray drying. The result is a technology with quick turnaround times which can be easily integrated in conventional drug manufacturing processes.. Each formulation can be protected by composition of matter patents and therefore is ideally suited for life-cycle management.
"We are optimistic that this agreement marks the first step of a broader strategic collaboration,” said Dr. Amir Zalcenstein, CEO of Solubest. "Dr. Reddy's was one of the first companies to show interest in our free formulation initiative. Although the agreement is for our lead pipeline product, we believe this validates our approach."
In line with its strategic focus, UCB announces it has entered an agreement with Dr. Reddy’s to sell its established brands in India, including its franchises in the areas of allergies and respiratory disorders. The amount of the transaction amounts to INR 8000 million (~ €118 million). The ... more
Dr. Reddy's and OctoPlus jointly announced that they have reached conditional agreement in connection with an intended public offer by Dr. Reddy's, or a wholly owned subsidiary of Dr. Reddy's, for all issued and outstanding ordinary shares in the capital of OctoPlus at an offer price of € 0 ... more
Merck and Dr. Reddy’s Laboratories Ltd. announced a partnership to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies (MAbs). The partnership covers co-development, manufacturing and commercialization of the compounds around the globe, wit ... more
SoluBest, has appointed Dr. Amir Zalcenstein as new CEO. > Dr. Zalcenstein joined SoluBest in 2007 as Business Development Manager and was appointed to Senior Director of Business Development in 2008. Prior to joining SoluBest he worked with Ernst & Young's GIA division as a senior consult ... more